New Data on Multiple Bristol-Myers Squibb Investigational Hepatitis C Compounds to be Presented at The International Liver Congress 2011

Data Demonstrate Focused Execution of the Company’s Hepatitis C R&D Strategy

PRINCETON, N.J.--(BUSINESS WIRE)--New Phase II data on multiple Bristol-Myers Squibb Company (NYSE: BMY) investigational hepatitis C compounds will be presented at The International Liver Congress (ILC), the 46th annual meeting of the European Association for the Study of the Liver (EASL) in Berlin, Germany, from March 30 to April 2. The data presentations, including three late-breaker presentations, demonstrate the rigorous execution of the company’s strategy to develop potential improvements in the care of patients living with Hepatitis C infection by using multiple approaches to target the virus.

Bristol-Myers Squibb will present three late-breaker presentations, including a poster presentation of the first public disclosure of 12-week data on sustained virologic response (SVR) with the NS5A inhibitor BMS-790052 in combination with PEG-Interferon alpha-2a and ribavirin (IFNα/RBV) in treatment-naïve HCV patients. Additionally, SVR 12-week data on quadruple therapy with BMS-790052, the NS3 inhibitor BMS-650032 and IFNα/RBV in null responders will be presented in the late-breaker oral presentation session on Saturday, April 2. Complete early virology response (cEVR) data from the Phase IIb EMERGE study of PEG-Interferon lambda and ribavirin versus IFNα/RBV in treatment-naïve patients will also be presented in a late-breaker oral presentation.

“Bristol-Myers Squibb is focused on advancing the science to address significant unmet medical needs for patients with liver disease,” said Brian Daniels, MD, senior vice president, Global Development and Medical Affairs, Research and Development, Bristol-Myers Squibb. “The data at the International Liver Congress reflect the breadth of our hepatitis C pipeline and the multiple approaches we are taking to bring forward potential new options for a disease that today impacts approximately 170 million people worldwide.”

BMS-790052 and BMS-650032 were discovered by Bristol-Myers Squibb Research and Development. PEG-Interferon lambda was discovered by ZymoGenetics, Inc., a wholly-owned subsidiary of Bristol-Myers Squibb.

The Bristol-Myers Squibb data presentations at ILC are as follows:

<table>
<thead>
<tr>
<th>Date/Time</th>
<th>Presentation Title</th>
<th>Lead Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>March 31</td>
<td>First report of SVR12 for a NS5A Replication complex inhibitor, BMS-790052 in combination with PEG-IFNα-2A and RBV: Phase 2a trial in treatment-naïve HCV-Genotype 1 subjects (Poster Board # 1373)</td>
<td>S. Pol Hôpital Cochin Paris, France</td>
</tr>
<tr>
<td>April 1</td>
<td>In Vitro DAA combination studies to address HCV clinical findings (Poster Board # 803)</td>
<td>J.A. Lemm Bristol-Myers Squibb</td>
</tr>
<tr>
<td>April 1, 4:45 – 5:00 p.m.</td>
<td>Characterization of Virologic Escape in HCV Genotype 1 Null responders receiving a combination of the NS3 protease inhibitor BMS-650032 and NS5A inhibitor BMS-790052 (Oral Session)</td>
<td>F. McPhee Bristol-Myers Squibb</td>
</tr>
<tr>
<td>April 2</td>
<td>BMS-650032, an NS3 inhibitor, in combination with PegInterferon Alfa-2a and Ribavirin in treatment-naïve subjects with genotype-1 chronic hepatitis C infection (Poster Board # 1195)</td>
<td>J. Bronowicki Hôpital Adultes De Brabois Vandeuvre Les Nancy, France</td>
</tr>
<tr>
<td>April 2</td>
<td>No early virologic breakthrough observed with the HCV NS3 protease inhibitor BMS-650032 in multiple dose monotherapy studies and Phase 2a combination studies with PEG-INF alpha/RBV (Poster Board # 1223)</td>
<td>F. McPhee Bristol-Myers Squibb</td>
</tr>
</tbody>
</table>
April 2

The burden of hepatitis C in Europe: a propensity analysis of patient outcomes
(Poster Board # 1192)
M. daCosta DiBonaventura
Kantar Health
New York, New York

April 2

Estimating the incidence and prevalence of hepatitis C infection in England using back projection methods (Poster Board # 1166)
P. McEwan
Cardiff Research Consortium
Cardiff, UK
Swansea University
Swansea, UK

April 2

Cost benefit analysis of response guided therapy: dynamic disease Markov modeling for patients with chronic hepatitis (HCV) by fibrosis stages (Poster Board # 1167)
P. McEwan
Cardiff Research Consortium
Cardiff, UK
Swansea University
Swansea, UK

April 2, 3:30 – 5:30 p.m.
Pegylated Interferon-Lambda (PEGIFN-λ) shows superior viral response with improved safety and tolerability versus PEGIFNα-2A in HCV patients (G1/2/3/4): EMERGE Phase IIb through week 12 (Late-Breakers Oral Session)
S. Zeuzem
Klinikum der Johann-Wolfgang Goethe-Universität, Frankfurt/Main, Germany

April 2, 3:30 – 5:30 p.m.
Quadruple therapy with BMS-790052, BMS-650032 and PEG-IFN/RBV for 24 weeks results in 100% SVR12 in HCV Genotype 1 null responders (Late-Breakers Oral Session)
A. Lok
University of Michigan
Ann Arbor, Michigan

**About Bristol-Myers Squibb**

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit [http://www.bms.com](http://www.bms.com) or follow us on Twitter at [http://twitter.com/bmsnews](http://twitter.com/bmsnews).

**Language:**
English

**Contact:**

Bristol-Myers Squibb
Media:
Cristi Barnett, 609-252-6028
cristi.barnett@bms.com
or
Investors:
John Elicker, 609-252-4611
john.elicker@bms.com

**Ticker Slug:**

*Ticker:* BMY  
*Exchange:* NYSE